SCHEMBL1605897

SCHEMBL1605897

Cc1c(Cl)cccc1NC1=NC(=O)C(CC(=O)O)S1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.46
ALDH1A1 P00352 3/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
HIF1A Q16665 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPK1 P28482 2/20 0.46
LMNA P02545 2/20 0.45
HPGD P15428 2/20 0.45
USP2 O75604 1/20 0.45
MT-CO2 P00403 1/20 0.45
TTR P02766 1/20 0.45
PLA2G1B P04054 1/20 0.45
CYP1A2 P05177 1/20 0.45
PGR P06401 1/20 0.45
HTR1A P08908 1/20 0.45
ADRA2A P08913 1/20 0.45
ADORA3 P0DMS8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6386607 0.85 MAPT (0.43) MAPTALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL6501538 0.78 MAPT (0.46) MAPTALDH1A1MEN1KMT2AHSD17B10
SCHEMBL6388619 0.78 LMNA (0.47) MAPTALDH1A1MEN1KMT2AMAPK1
SCHEMBL1605128 0.77 NISCH (0.41) MAPTCYP3A4CYP2C9CYP2C19HIF1A
SCHEMBL6505857 0.76 MAPT (0.45) MAPTALDH1A1CYP2C19MEN1KMT2A
SCHEMBL1383105 0.74 CDK5 (0.39) MAPTALDH1A1CYP3A4CYP2C19KMT2A
SCHEMBL6388541 0.74 MAPT (0.46) MAPTALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL6498552 0.72 P2RX7 (0.46) MAPTALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL6502404 0.71 ALDH1A1 (0.49) MAPTALDH1A1CYP3A4CYP2C9CYP2C19
SCHEMBL6506396 0.70 P2RX7 (0.45) MAPTALDH1A1CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541592-B2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 AMGEN INC. (US) 2013-09-24 US disclosed
US-20110082107-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AMGEN INC. 2011-04-07 US disclosed
US-7807700-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 AMGEN INC. (US) 2010-10-05 US disclosed
US-20080045503-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2008-02-21 US disclosed
US-20070281938-A1 Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 AMGEN INC. 2007-12-06 US disclosed
US-20070197598-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2007-08-23 US disclosed
US-7253196-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 AMGEN, INC. (US) 2007-08-07 US disclosed
US-20060142357-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2006-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082107-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD3B1, HSD17B1 MAPT 3588/4885ALDH1A1 100/4885CYP3A4 158/4885
US-20080045503-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD3B1, HSD17B1 MAPT 3588/4885ALDH1A1 100/4885CYP3A4 158/4885
US-20070197598-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 MAPT 2825/4885ALDH1A1 71/4885CYP3A4 280/4885
US-20060142357-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD3B1, HSD17B1 MAPT 3588/4885ALDH1A1 100/4885CYP3A4 158/4885
US-20070281938-A1 Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 HSD11B1, HSD3B1, HSD17B1 MAPT 3804/4885ALDH1A1 76/4885CYP3A4 90/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.